While rumors of a spin have long swirled around the company, the speculation really heated up after activist investor Cevian recently took an 18% stake in the company. Analysts seem to like the move as a catalyst to unlock value and break up the conglomerate discount. Supposedly, CEO Nick Salmon is receptive to the idea of a split although I am not sure what the source of that info is. Although the share price is still lagging its peers, the name is up big year to date and it even popped a bit on the day of the announcement.
For some additional information on the company, check out its most recent annual report where it surprised with 11+% profit growth. While there is an OTC vehicle to trade here, it appears extremely thinly traded and of course, one must keep in mind the foreign exchange risk when purchasing a foreign denominated company.
Disclosure: Author holds no position in any stock mentioned.